|
|
|
|
Genetix gets $35m infusion for gene therapy work
Venture capitalists are giving the risky field of gene therapy a new dose of confidence?and cash? Genetix Pharmaceuticals, a 17-year-old developer of gene therapies, has replenished its coffers with a $35 million Series B round of...
|
|
|
Wiley-Blackwell: Targeting leukemia cell's gene 'addiction' presents new strategy for treatment
Today's Medical & Research News Wiley-Blackwell Targeting leukemia cell's gene 'addiction' presents new strategy for treatment March 15th, 2010 Printer-Friendly Version Addiction Medicine Antineoplastic Biotechnology Drug Development Hematology...
|
|
|
Iverson Genetic Diagnostics, Inc. to Sponsor the WARFARIN Study Designed to Address National Coverage and Safe
The WARFARIN Study Will Assess the Extent to Which Gene Identification Can Improve Safety in Warfarin Dosing ATLANTA--(BUSINESS WIRE)--Mar 15, 2010 - Iverson Genetic Diagnostics, Inc.today announced that they will conduct a WARFARIN clinical study to...
|
|
|
The Leukemia & Lymphoma Society and FORMA Therapeutics Enter a Drug Discovery Alliance to Discover and Develop Novel Therapies For Patients with Diffuse Large B Cell Lymphoma
WHITE PLAINS, N.Y.& CAMBRIDGE, Mass.The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6. This new...
|
|
|
The Leukemia & Lymphoma Society and FORMA Therapeutics Enter a Drug Discovery Alliance to Discover and Develop Novel Therapies For Patients with Diffuse Large B Cell Lymphoma
WHITE PLAINS, N.Y.& CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target,...
|
|
|
The Leukemia & Lymphoma Society and FORMA Therapeutics Enter a Drug Discovery Alliance to Discover and Develop Novel
Therapies For Patients with Diffuse Large B Cell Lymphoma WHITE PLAINS, N.Y.& CAMBRIDGE, Mass. - (BUSINESS WIRE) - The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover...
|
|
|
The Leukemia & Lymphoma Society and FORMA Therapeutics Enter a Drug Discovery Alliance to Discover and Develop Novel Therapies For Patients with Diffuse Large B Cell Lymphoma
WHITE PLAINS, N.Y.& CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target,...
|
|
|
Designer Babies
Blog this on: Until just a few years ago, making a baby boy or a baby girl was pretty much a hit-or-miss affair.Not anymore. Parents who have access to the latest genetic testing techniques can now predetermine their baby's sex with great accuracy--as...
|
|
|
Gene test can predict colon cancers return
US researchers say theyve developed a genetic model for predicting the risk of recurrence in patients with early stage colon cancer.According to a team at the Duke Institute for Genome Science & Policy, the model also predicts colon cancers sensitivity to...
|
|
|
Gene test can predict colon cancer's return
US researchers say they've developed a genetic model for predicting the risk of recurrence in patients with early stage colon cancer.According to a team at the Duke Institute for Genome Science & Policy, the model also predicts colon cancer's sensitivity...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
More than one out of four patients in analysis had variant in ABCB1 gene PR Newswire PARSIPPANY, N.J.and INDIANAPOLIS, March 15 /PRNewswire-FirstCall/ -- A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
More than one out of four patients in analysis had variant in ABCB1 gene PARSIPPANY, N.J.and INDIANAPOLIS, March 15 /PRNewswire-FirstCall/ -- A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant...
|
|
|
The Leukemia & Lymphoma Society and FORMA Therapeutics Enter a Drug Discovery Alliance to Discover and Develop
Cancer Breaking News News source: Business Wire The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
/PRNewswire via COMTEX/ ----A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix ...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix ...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix ...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix ...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix ...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix ...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix ...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix ...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix ...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene.Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix ...
|
|
|
New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy
PARSIPPANY, N.J.and INDIANAPOLIS, March 15 /PRNewswire-FirstCall/ -- A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were...
|
